Moleculin Announces Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations For Multiple Data Readouts And Transition To Pivotal Phase 2B/3
Portfolio Pulse from Benzinga Newsdesk
Moleculin Biotech, Inc. has released preliminary data from its Annamycin clinical trials, showing positive outcomes in treating acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The MB-106 AML trial has reached 67% recruitment with a CR rate of 40% and a CR/CRi rate of 47%. The first AML patient treated achieved a CR, and no CR/CRi patients have relapsed. The MB-107 STS Lung Mets trial reported a median overall survival of 11 months in heavily pre-treated subjects. All Annamycin subjects across multiple studies have shown no signs of cardiotoxicity. Moleculin anticipates multiple data readouts and a transition to pivotal Phase 2B/3 in 2024.
January 24, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moleculin's preliminary clinical trial data for Annamycin indicates positive treatment outcomes for AML and STS lung metastases, with no observed cardiotoxicity and expectations for pivotal trials in 2024.
The positive preliminary data from Moleculin's clinical trials suggest potential for Annamycin as an effective treatment for AML and STS lung metastases, which could lead to increased investor confidence and a positive short-term impact on MBRX's stock price. The lack of cardiotoxicity is a significant positive as it addresses a common concern with cancer treatments. The anticipation of multiple data readouts and the transition to pivotal Phase 2B/3 trials in 2024 could maintain investor interest and support stock momentum.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100